Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population

Chin Med J (Engl). 2020 Oct 26;134(1):117-119. doi: 10.1097/CM9.0000000000001179.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • China
  • Humans
  • Psoriasis* / drug therapy
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • secukinumab